Immunogenicity of Fractional Dose of the HPV Vaccines

HPV Infection Clinical Trial

Official title:

Immunogenicity of Fractional Dose of the HPV Vaccines

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05291871
• Other study ID #: STUDY00014983
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: June 15, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: University of Washington
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 92
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 27 Years to 45 Years

Eligibility

Inclusion Criteria:

• Age 27-45 years at enrollment

• Not intending to receive the HPV vaccine series for the duration of the study participation

• Willing and able to: provide written informed consent, undergo clinical evaluation, adhere to follow-up schedule

Exclusion Criteria:

• Prior immunization with HPV-vaccine (Cervarix, Gardasil-4, Gardasil-9)

• Currently pregnant or breastfeeding

• Immunedeficiency disease/condition or cancer that causes clinically significant immunosuppression

• Known HIV infection

• Chemotherapy (current or within 12 months) or currently taking a medication that causes clinically significant immunosuppression.

• Unstable medical condition (e.g., malignant hypertension, poorly controlled diabetes)

• Known allergy to vaccine components

• Prior history of HPV-associated cancer

• Any medical condition which, in the opinion of the investigator, may compromise the subject's ability to safely complete the study.

Related Conditions & MeSH terms

• HPV Infection
• HPV Vaccine
• Papillomavirus Infections

Intervention

Biological:
• HPV vaccine
One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine

Locations

Country	Name	City	State
United States	University of Washington Virology Research Clinic	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HPV antibody detection after intradermal or intramuscular, fractional one-fifth dose HPV-2 or HPV-9 vaccine immunization	To describe the changes in vaccine-type HPV antibody detection measured by Luminex assay between baseline and 12 months after vaccination.	12 months